Infliximab [infliximab biosimilar 3] ( DrugBank: Infliximab )

4 diseases

ID	Disease name (Link within this page)	Number of trials
37	Generalised pustular psoriasis	1
46	Malignant rheumatoid arthritis	1
96	Crohn disease	1
97	Ulcerative colitis	1

37. Generalised pustular psoriasis

Clinical trials : 79 / Drugs : 57 - (DrugBank : 21) / Drug target genes : 20 - Drug target pathways : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03885089 (ClinicalTrials.gov)	October 21, 2019	4/3/2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Psoriasis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis)	Psoriasis Vulgaris;Psoriasis Arthropathica;Pustular Psoriasis;Erythrodermic Psoriasis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	0 Years	N/A	All	100		Japan

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03885037 (ClinicalTrials.gov)	March 20, 2019	4/3/2019	Infliximab Biosimilar for Intravenous Drip Infusion 100 mg Pfizer Drug Use Investigation (Rheumatoid Arthritis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Rheumatoid Arthritis)	Rheumatoid Arthritis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	0 Years	N/A	All	300		Japan

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03884439 (ClinicalTrials.gov)	March 18, 2019	4/3/2019	Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or Ulcerative Colitis)	Crohn's Disease;Ulcerative Colitis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Enrolling by invitation	0 Years	N/A	All	300		Japan

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03884439 (ClinicalTrials.gov)	March 18, 2019	4/3/2019	Infliximab Biosimilar Pfizer Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or Ulcerative Colitis)	Crohn's Disease;Ulcerative Colitis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Enrolling by invitation	0 Years	N/A	All	300		Japan